CoChat

Mesenchymal Stem Cell: A Friend or Foe in Anti-Tumor Immunity

Open access
Harrell, Carl Randall, Volarevic, Ana, Djonov, Valentin G., Jovicic, Nemanja, Volarevic, Vladislav · 2021 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Abstract

Mesenchymal stem cells (MSCs) are self-renewable, multipotent stem cells that regulate the phenotype and function of all immune cells that participate in anti-tumor immunity. MSCs modulate the antigen-presenting properties of dendritic cells, affect chemokine and cytokine production in macrophages and CD4+ T helper cells, alter the cytotoxicity of CD8+ T lymphocytes and natural killer cells and regulate the generation and expansion of myeloid-derived suppressor cells and T regulatory cells. As plastic cells, MSCs adopt their phenotype and function according to the cytokine profile of neighboring tumor-infiltrated immune cells. Depending on the tumor microenvironment to which they are exposed, MSCs may obtain pro- and anti-tumorigenic phenotypes and may enhance or suppress tumor growth. Due to their tumor-homing properties, MSCs and their exosomes may be used as vehicles for delivering anti-tumorigenic agents in tumor cells, attenuating their viability and invasive characteristics. Since many factors affect the phenotype and function of MSCs in the tumor microenvironment, a better understanding of signaling pathways that regulate the cross-talk between MSCs, immune cells and tumor cells will pave the way for the clinical use of MSCs in cancer immunotherapy. In this review article, we summarize current knowledge on the molecular and cellular mechanisms that are responsible for the MSC-dependent modulation of the anti-tumor immune response and we discuss different insights regarding therapeutic potential of MSCs in the therapy of malignant diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms222212429

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 MSC-based suppression of anti-tumor immunity. MSCs promote tumor growth by: (i) preventing DC-based cysteine delivery to T cells, (ii) inducing alternative activation of tumor-associated macrophages, (iii) suppressing production of TNF-α, IFN-γ and IL-17 in CD4+T helper cells, (iv) inhibiting cytotoxicity of FASL on CTLs and NK cells (down-regulated expression of FASL and TRAIL; reduced secretion of perforins and granzymes) and (v) promoting generation and expansion of Tregs and MDSCs. The red triangles represent increased number of cells and their products; the blue triangles represent the decreased number of cells and their products.
Figure 1 MSC-based suppression of anti-tumor immunity. MSCs promote tumor growth by: (i) preventing DC-based cysteine delivery to T cells, (ii) inducing alternative activation of tumor-associated macrophages, (iii) suppressing production of TNF-α, IFN-γ and IL-17 in CD4+T helper cells, (iv) inhibiting cytotoxicity of FASL on CTLs and NK cells (down-regulated expression of FASL and TRAIL; reduced secretion of perforins and granzymes) and (v) promoting generation and expansion of Tregs and MDSCs. The red triangles represent increased number of cells and their products; the blue triangles represent the decreased number of cells and their products.CC BY · PubMed Central
Figure 2 MSC-EVs as potentially new therapeutic agents in immunotherapy of malignant diseases. MSC-EVs deliver anti-tumorigenic miRNAs directly into tumor cells, altering their viability, proliferation rate and invasive characteristics. MSC-EV-sourced miRNA-16-5p and miRNA-3940-5p inhibited migratory properties and metastatic potential of tumor cells by down-regulating expression of integrins ITGA2 and ITGA6 on their membranes. MSC-EV-delivered miRNA-4461 suppressed proliferation and invasive properties of tumor cells by reducing expression of COPB2, which is essential for Golgi budding and vesicular trafficking. MSC-EVs carrying miRNA-15a inhibit the immune escape of tumor cells by regulating expression of HOXC4, which binds to the promoter sequence of PDL1, controlling its synthesis and membrane expression. MSC-derived miRNA-15a induces apoptosis of tumor cells by inhibiting activity of KDM4B which epigenetically regulates chromatin structure. The MSC-EV-delivered miRNA-100 down-regulates production of VEGF in cancer cells, preventing generation of new blood vessels in growing tumors. The red triangle represents increased and the blue triangles represent decreased activity.
Figure 2 MSC-EVs as potentially new therapeutic agents in immunotherapy of malignant diseases. MSC-EVs deliver anti-tumorigenic miRNAs directly into tumor cells, altering their viability, proliferation rate and invasive characteristics. MSC-EV-sourced miRNA-16-5p and miRNA-3940-5p inhibited migratory properties and metastatic potential of tumor cells by down-regulating expression of integrins ITGA2 and ITGA6 on their membranes. MSC-EV-delivered miRNA-4461 suppressed proliferation and invasive properties of tumor cells by reducing expression of COPB2, which is essential for Golgi budding and vesicular trafficking. MSC-EVs carrying miRNA-15a inhibit the immune escape of tumor cells by regulating expression of HOXC4, which binds to the promoter sequence of PDL1, controlling its synthesis and membrane expression. MSC-derived miRNA-15a induces apoptosis of tumor cells by inhibiting activity of KDM4B which epigenetically regulates chromatin structure. The MSC-EV-delivered miRNA-100 down-regulates production of VEGF in cancer cells, preventing generation of new blood vessels in growing tumors. The red triangle represents increased and the blue triangles represent decreased activity.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Show all 47 references

Cited by

See all 67

Metadata

Authors
Harrell, C. R., Volarevic, A., Djonov, V. G., Jovicic, N., & Volarevic, V.
Affiliations
  • Regenerative Processing Plant, LLC, 34176 US Highway 19 N, Palm Harbor, FL 34684, USA
  • University of Kragujevac (RS)
  • University of Bern (CH)
  • Department of Genetics, Faculty of Medical Sciences, University of Kragujevac, 69 Svetozar Markovic Street, 34000 Kragujevac, Serbia
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2021-11-18
Volume
22
Issue
22
Pages
12429
ISSN
1422-0067 (ISSN-L)
OpenAlex
W3213583932
Cited by
67
References
47
Citations by year
2026: 9 · 2025: 14 · 2024: 23 · 2023: 17 · 2022: 4
FWCI
1.57
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • European Crohn’s and Colitis Organization (ECCO) (“The role of galectin 3 in acute colitis”)
  • Swiss National Science Foundation (IZSEZ0 185546)
  • Serbian Ministry of Science (ON1275069 and ON175071)
  • Faculty of Medical Sciences University of Kragujevac (MP01/18)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords
mesenchymal stem cells, antitumor immunity, tumor microenvironment, dendritic cells, macrophages, CD4+ T helper cells, CD8+ T cells, natural killer cells, myeloid-derived suppressor cells, regulatory T cells, tumor homing, exosomes, cancer immunotherapy
MeSH terms
Cell Communication, Cell Differentiation, Dendritic Cells, Gene Expression Regulation, Humans, Immunity, Innate, Immunotherapy, Killer Cells, Natural, Macrophages, Neoplasms, T-Lymphocytes, Cytotoxic, Mesenchymal Stem Cell Transplantation, T-Lymphocytes, Regulatory, Exosomes, Tumor Microenvironment, Mesenchymal Stem Cells, B7-H1 Antigen, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mesenchymal Stem Cell: A Friend or Foe in Anti-Tumor Immunity. https://app.cochat.ai/papers/10.3390/ijms222212429
The paper
Harrell, C. R., Volarevic, A., Djonov, V. G., Jovicic, N., & Volarevic, V. (2021). Mesenchymal Stem Cell: A Friend or Foe in Anti-Tumor Immunity. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms222212429

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.